Incidences of malignant neoplasms were low and stable with long-term ixekizumab treatment for people with psoriatic disease ...

Some medicines used for heart problems, like beta-blockers, ACE inhibitors, and calcium channel blockers, have been known to ...

Patients with ID receiving TNF inhibitors are at greater risk for cutaneous malignancy than patients who are biologic-naïve.

Nearly nine million people in the U.S. have an inflammatory skin condition called plaque psoriasis. We're raising awareness ...

Lady T is joined by Dr. Mona Gohara, Medical Dermatologist and Associate Clinical Professor at the Department of Dermatology ...

This segment is sponsored by Arcutis Biotherapeutics.Nearly 9 million people in the U.S. have an inflammatory skin condition ...

A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council ...

For patients with psoriasis and Type 2 diabetes, the risk of developing chronic kidney disease (CKD) continued to rise ...

AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and ...

The American Academy of Dermatology/National Psoriasis Foundation (AAD/NPF) guidelines state that "topical medications are the most common agents used to treat patients with mild or moderate ...

There's no sure way to prevent psoriatic arthritis, but managing certain risk factors may reduce the chances of developing it for people with psoriasis.